Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Period	Debt/Equity
2015-12-31	0.15
2016-12-31	0.20
2017-12-31	0.30
2018-12-31	2.18
2019-12-31	2.50
2020-12-31	2.46
2021-12-31	2.41
2022-12-31	5.03
2023-12-31	4.85
2024-12-31	6.27

	A	B	C	D
1	Symbol	Price	Change	Volume
2	COLL	$32.31	+0.00%	0.58M
3
4
5

Collegium Pharmaceutical Inc. (COLL) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Collegium Pharmaceutical Inc. Data in Excel

More COLL Financial Data